| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 523 | 571 | 558 | 583 | 745 | 845 | 826 | 820 | 1,029 | 1,330 | 1,757 | 1,899 |
| Expenses | 529 | 547 | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,598 |
| EBITDA | -6 | 23 | 51 | 59 | 88 | 134 | 148 | 101 | 191 | 219 | 295 | 301 |
| Operating Profit % | -2 % | 3 % | 7 % | 8 % | 10 % | 15 % | 17 % | 11 % | 16 % | 14 % | 15 % | 14 % |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 53 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit Before Tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 246 |
| Tax | 0 | 1 | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 | 41 | 72 |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 183 |
| EPS in ₹ | -8.34 | 2.10 | 8.00 | 10.40 | 21.80 | 28.90 | 37.30 | 24.60 | 39.70 | 64.60 | 46.30 | 74.30 |
AstraZeneca Pharma
AstraZeneca Pharma
9,302.50
-4.00
(-0.04%)
Key Fundamentals
Market Cap
23,252.50 Cr
EPS
46.30
PE Ratio
126.67
Dividend Yield
0.34 %
Industry
Healthcare 52 Week High
10,691.00
52 Week Low
6,220.00
PB Ratio
30.15
Debt to Equity
0.03
Sector
Pharmaceuticals Actual
Company News
View All News
AstraZeneca Pharma India Limited announced the launch of Sodium Zirconium Cyclosilicate powder (Lokelma) for oral suspension in November 2025. The company received Import and Marketing Permission from the Drugs Controller General of India in March 2025. The 5g oral suspension product is indicated for treating hyperkalaemia in adult patients. The company had previously obtained regulatory approval for both 5g and 10g formulations but is launching the 5g version first.
The Trump Administration has reached a drug pricing agreement with AstraZeneca. Under the deal, AstraZeneca will receive a three-year tariff exemption in exchange for providing discounts on Medicaid prescriptions.
AstraZeneca's CEO announced plans to provide select drugs at up to 80% discount through the TrumpRx website next year. The Trump Administration has reached a drug pricing agreement with AstraZeneca that includes a three-year tariff exemption for Medicaid discounts.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,699.00 | #1 4,05,463.60 | 39.22 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 66.09 | |
6,593.00 | 1,74,293.40 | 75.84 | 9,712.00 | 18.67 | 2,191 | 26.74 | 69.16 | |
1,584.40 | 1,32,883.60 | 23.76 | 28,409.50 | 7.12 | 5,291 | 9.88 | 53.71 | |
3,581.40 | 1,22,317.60 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 52.12 | |
1,283.60 | 1,07,131.00 | #1 18.66 | 33,741.20 | 16.73 | 5,725 | -0.38 | 56.05 | |
1,004.90 | 1,01,529.00 | 21.48 | 23,511.00 | 18.55 | 4,615 | 2.60 | 52.84 | |
2,432.40 | 1,01,167.10 | 52.47 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.94 | |
1,931.20 | 88,601.20 | 23.70 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 45.02 | |
5,545.00 | 66,167.30 | 28.42 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.03 | |
29,930.00 | 63,992.30 | 43.81 | 6,684.70 | 9.64 | 1,414 | 11.55 | 43.69 |
Growth Rate
Revenue Growth
32.07 %
Net Income Growth
-28.36 %
Cash Flow Change
134.52 %
ROE
-33.80 %
ROCE
-36.77 %
EBITDA Margin (Avg.)
1.76 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
| Fixed Assets | 101 | 97 | 87 | 76 | 75 | 72 | 81 | 75 | 69 | 67 | 64 |
| Current Assets | 263 | 267 | 252 | 321 | 405 | 542 | 619 | 706 | 836 | 933 | 1,342 |
| Capital Work in Progress | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 |
| Total Liabilities | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
| Current Liabilities | 260 | 234 | 190 | 207 | 259 | 327 | 304 | 333 | 384 | 357 | 703 |
| Non Current Liabilities | 1 | 13 | 2 | 7 | 2 | 15 | 15 | 13 | 12 | 9 | 45 |
| Total Equity | 151 | 156 | 223 | 247 | 301 | 364 | 456 | 511 | 589 | 712 | 770 |
| Reserve & Surplus | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 |
| Investing Activities | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 |
| Operating Activities | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 |
| Financing Activities | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -10 | -25 | -44 | -66 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.69 % | 0.00 % | 2.74 % | 2.79 % | 2.90 % | 2.93 % | 2.89 % | 3.03 % |
| DIIs | 0.83 % | 0.94 % | 0.96 % | 1.00 % | 1.02 % | 1.10 % | 1.12 % | 1.44 % | 1.42 % | 1.93 % | 2.43 % | 2.75 % | 3.78 % | 5.01 % | 5.10 % | 5.22 % | 4.65 % | 4.56 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.53 % | 19.72 % | 19.69 % | 19.44 % | 19.06 % | 18.62 % | 18.54 % | 18.56 % | 18.46 % | 18.12 % | 17.44 % | 17.09 % | 16.33 % | 15.00 % | 14.77 % | 14.62 % | 15.16 % | 15.18 % |
| Others | 4.64 % | 4.34 % | 4.34 % | 4.57 % | 4.92 % | 5.28 % | 5.34 % | 5.01 % | 5.12 % | 4.95 % | 2.44 % | 5.15 % | 2.15 % | 2.20 % | 2.23 % | 2.24 % | 2.31 % | 2.23 % |
| No of Share Holders | 0 | 63,753 | 68,077 | 66,444 | 62,183 | 57,760 | 53,980 | 49,085 | 42,146 | 38,946 | 32,380 | 29,032 | 29,418 | 27,169 | 27,615 | 27,322 | 32,466 | 34,378 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 2 | 10 | 16 | 24 | 32 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | 0.31 | 0.3 | 0.28 | 0.34 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 20 Aug 2021 |  Dividend | ₹ 2.00 /share | 18 Aug 2021 | 3,406.35 | 3,101.65 |
| 08 Jul 2022 | Dividend | ₹ 8.00 /share | 07 Jul 2022 | 2,635.15 | 2,898.90 |
| 08 Aug 2022 |  Annual General Meeting | NA | 08 Aug 2022 | 2,982.60 | 3,079.00 |
| 14 Jul 2023 | Dividend | ₹ 16.00 /share | 14 Jul 2023 | 3,253.00 | 3,767.35 |
| 05 Jul 2024 | Dividend | ₹ 24.00 /share | 05 Jul 2024 | 6,011.75 | 7,120.15 |
| 08 Aug 2024 | Annual General Meeting | NA | 08 Aug 2024 | 6,610.75 | 7,090.80 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 7,155.25 | 7,410.50 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 6,920.30 | 7,535.10 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 7,920.85 | 7,918.50 |
| 18 Jul 2025 | Dividend | ₹ 32.00 /share | 18 Jul 2025 | 7,918.50 | 9,386.25 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 8,953.35 | 8,416.50 |
| 14 Aug 2025 | Annual General Meeting | NA | 14 Aug 2025 | 8,832.65 | 8,416.50 |
Announcements
Launch Of Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5G (Lokelma)
10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Oct 03, 2025
Oct 03, 2025Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 19, 2025
Sep 19, 2025Closure of Trading WindowSep 12, 2025
Sep 12, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 12, 2025
Sep 12, 2025Disclosure under Regulation 30A of LODRSep 12, 2025
Sep 12, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Sep 10, 2025
Sep 10, 2025Disclosure under Regulation 30A of LODRSep 02, 2025
Sep 02, 2025Disclosure under Regulation 30A of LODRSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Aug 19, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 18, 2025
Aug 18, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2025
Aug 14, 2025Outcome Of The Board Meeting Held On Thursday August 14 2025Aug 14, 2025
Aug 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Aug 12, 2025
Aug 12, 2025Launch Of Eculizumab (Soliris)Aug 06, 2025
Aug 06, 2025Clarification On News Item Appearing In Https://Www.Moneycontrol.ComAug 01, 2025
Aug 01, 2025Clarification sought from AstraZeneca Pharma India LtdAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday August 14 2025Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 46Th Annual General MeetingJul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Communication To The Shareholders W.R.T. TDS On DividendJul 21, 2025
Jul 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 16, 2025
Jul 16, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 14, 2025
Jul 14, 2025Disclosure under Regulation 30A of LODRJul 11, 2025
Jul 11, 2025Record Date For Payment Of Final DividendJul 11, 2025
Jul 11, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 01, 2025
Jul 01, 2025Determination Of Materiality - Details Of Key Managerial PersonnelJul 01, 2025
Jul 01, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jun 20, 2025
Jun 20, 2025Closure of Trading WindowJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Resignation of Managing DirectorJun 09, 2025
Jun 09, 2025Disclosure under Regulation 30A of LODRJun 07, 2025
Jun 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Secretarial AuditorMay 30, 2025
May 30, 2025Outcome Of The Board Meeting Held On Friday May 30 2025
May 30, 2025
May 30, 2025Board Meeting Outcome for Recommendation Of Dividend For The Financial Year 2024-25May 30, 2025
May 30, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015May 30, 2025
May 30, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015May 29, 2025
May 29, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday May 30 2025May 21, 2025
May 21, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements)
Regulation 2015May 08, 2025
May 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018May 08, 2025
May 08, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Apr 15, 2025
Apr 15, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 14, 2025
Apr 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Mutual Fund Holdings
Bandhan Large & Mid Cap Fund Direct-Growth 
ICICI Prudential Multicap Fund Direct Plan-Growth 
Samco Flexi Cap Fund Direct - Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
UTI MNC Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Baroda BNP Paribas Manufacturing Fund Direct - Growth 
Groww Value Fund Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 57.93
ATR(14)
Less Volatile 190.98
STOCH(9,6)
Neutral 59.33
STOCH RSI(14)
Neutral 52.26
MACD(12,26)
Bearish -1.24
ADX(14)
Weak Trend 19.34
UO(9)
Bearish 56.83
ROC(12)
Downtrend And Accelerating -0.84
WillR(14)
Neutral -39.50
About AstraZeneca Pharma
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.
Website
Chairperson NameShilpa Divekar Nirula
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
